WO2014163535A1 - Химерный пептид и фармацевтическая композиция для лечения онкологических заболеваний - Google Patents
Химерный пептид и фармацевтическая композиция для лечения онкологических заболеваний Download PDFInfo
- Publication number
- WO2014163535A1 WO2014163535A1 PCT/RU2014/000199 RU2014000199W WO2014163535A1 WO 2014163535 A1 WO2014163535 A1 WO 2014163535A1 RU 2014000199 W RU2014000199 W RU 2014000199W WO 2014163535 A1 WO2014163535 A1 WO 2014163535A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cancer
- seq
- peptide
- cells
- treatment
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
Definitions
- the present invention relates to the field of biotechnology and medicine, in particular, to new sequences of a chimeric peptide comprising a functional fragment and a transport sequence, the functional fragment comprising an amino acid sequence selected from the group SEQ ID NO: 1 - SEQ ID NO: 17, and 60% or more homologous to them; as well as to a functional peptide with antiproliferative activity, represented by an amino acid sequence selected from the group of SEQ ID NO: 1 - SEQ ID NO: 17, as well as homologous to them in 60% or more sequences.
- the invention also relates to the use of the aforementioned chimeric peptide for the treatment of cancer, as well as to a pharmaceutical composition having antiproliferative activity and a method for treating cancer, comprising administering said chimeric peptide to a mammal in need of such treatment.
- the objective of the invention is to develop a drug that effectively penetrates into target cells and has a high cytostatic and cytotoxic effect.
- cyclin kinases The activity of cyclin kinases is determined by the expression level of the corresponding cyclins and activity of specific cyclin kinase inhibitors (Kastan M.V., Bartek J., 2004). There are several families of cyclin kinase inhibitors. The most studied and practically important of them are pl6INK4a, p21CIP KIP, p27 KIP1 (Lowe SW et al.,
- cyclin kinase inhibitors were synthesized. Another possible direction for creating cyclin kinase inhibitors may be the use of functional sequences from the corresponding intracellular inhibitors (Ziegler A. et al., 2005). Protein p16 INK4a is one of the most interesting candidates for the Cdk inhibitor group (Xu D. et al., 2004; Zhang Y. et al., 2005). Protein pl6INK4a is known to inhibit cyclin-dependent kinases D and thereby the passage of the G1 phase of the cell cycle (Fu G.H. et al, 2005; Ben-Saadon R. et al., 2004).
- peptides capable of penetrating into the cell without the participation of membrane proteins and capable of carrying out intracellular transport of protein fragments and oligonucleotides associated with them opens a new stage in the development of biology and medicine.
- One of the effective carriers of large molecules inside cells is the pAntp peptide. Its properties are known, in particular, from the publications of Derossi D. et al .. The third helix of the Antennapedia homeodamain translocates through membranes.// J. Biol. Chem. 269 (1994) 10444-10450 and Morris MC. et al. A peptides carrier for the delivery of biologically active proteins in mammalian cells.// Nat. Biotechnology 19 (2001) 1173-1176.
- the closest analogue of the present invention is the patent US 6569833 B1 (Cyclacel Limited, GB).
- peptides that bind to cyclin kinases cleave and include amino acid residues 84-103 of the full-chain p16 protein and can be combined with the penetratin transport protein sequence through a disulfide bond formed between cysteine residues specifically attached to the C-terminus of the p16 and ⁇ - peptide end of the Antp peptide.
- the disadvantage of this approach is the need for selective and multi-stage synthesis of a chimeric molecule, which complicates the scheme for obtaining the target product and increases the overall time spent on synthesis.
- the present invention relates to the field of biotechnology and medicine.
- the objective of the invention is the creation of a new chimeric peptide that has an increased therapeutic effect and does not require a complex and laborious scheme for its preparation.
- the technical result of the present invention is an improved biomedical effect, objectively manifested in the pronounced cytotoxic effect of the specified chimeric peptide in comparison with other similar peptides on tumor cells of diseases such as colorectal cancer, kidney cancer, lung cancer, breast cancer, bladder cancer, pancreatic cancer, uterine cancer, prostate cancer, stomach cancer, ovarian cancer, myeloma, malignant lymphoma, and fibroadenomas of the mammary gland, in addition, simplifying the scheme for producing a chimeric peptide by reducing the total number of stages.
- the second technical result is the expansion of the arsenal of drugs for the treatment of cancer.
- the author of the present invention unexpectedly found a pronounced synergistic effect when sharing the above chimeric peptide with existing chemotherapeutic antitumor drugs Hetoposide. taxol and 5-fluorouracil).
- the technical result is achieved by obtaining a chimeric peptide with antiproliferative activity containing a functional fragment and a transport sequence, while the functional fragment includes the amino acid sequence of SEQ ID NO: 1 or SEQ ID NO: 2, or SEQ ID NO: 3, or SEQ ID NO: 4 or SEQ ID NO: 5 or SEQ ID NO: 6 or SEQ ID NO: 7 or SEQ ID NO: 8 or SEQ ID NO: 9 or SEQ ID NO: 10 or SEQ ID NO: 11 or SEQ ID NO: 12 or SEQ ID NO: 13 or SEQ ID NO: 14 or SEQ ID NO: 15 or SEQ ID NO: 16 or SEQ ID NO: 17, and also 60% or more homologous to them.
- the present invention relates to a functional peptide with antiproliferative activity, comprising the amino acid sequence of SEQ ID NO: 1 or SEQ ID NO: 2, or SEQ ID NO: 3, or SEQ ID NO: 4 SEQ ID NO: 5 or SEQ ID NO: 6 or SEQ ID NO: 7 or SEQ ID NO: 8 or SEQ ID NO: 9 or SEQ ID NO: 10 or SEQ ID NO: 11 or SEQ ID NO: 12 or SEQ ID NO: 13 or SEQ ID NO: 14 or SEQ ID NO: 15 or SEQ ID NO: 16 or SEQ ID NO: 17 as well as homologous to them by 60% or more of the sequence.
- the present invention relates to the use of said chimeric peptide for the manufacture of a medicament for the treatment of cancer.
- the present invention relates to a chimeric peptide comprising a functional peptide represented by the amino acid sequence of SEQ ID NO: 1 or SEQ ID NO: 2, or SEQ ID NO: 3, or SEQ ID NO: 4.
- the present invention relates to a functional peptide represented by the amino acid sequence of SEQ ID NO: 1 or SEQ ID NO: 2, or SEQ ID NO: 3, or SEQ ID NO: 4.
- the present invention relates to a chimeric peptide that can be used to treat a malignant tumor selected from the group consisting of colorectal cancer, kidney cancer, lung cancer, breast cancer, bladder cancer, pancreatic cancer, uterine cancer, prostate cancer, stomach cancer, ovarian cancer, myeloma and malignant lymphoma.
- the chimeric peptide can be used to treat colorectal cancer.
- said drug can be used to treat a cancer selected from the group consisting of colorectal cancer, kidney cancer, lung cancer, breast cancer, bladder cancer, pancreatic cancer, uterine cancer, prostate cancer, stomach cancer, ovarian cancer, myeloma and malignant lymphoma.
- the present invention relates to a pharmaceutical composition having antiproliferative activity, which comprises, as a therapeutically active substance, the above chimeric peptide or functional peptide in combination with pharmaceutically acceptable carriers.
- the present invention relates to a pharmaceutical composition having antiproliferative activity, which contains two active substances, where the first active substance is the aforementioned chimeric peptide or functional peptide, and the second active substance can be a chemotherapeutic antitumor agent selected from the group including alkylating drugs, antimetabolites, plant alkaloids, antitumor antibiotics, derivatives platinum derivatives, camptothecin derivatives, altretamine, amsacrine, L-asparaginase, dacarbazine, estramustine, hydroxycarbamide, procarbazine, temozolomide, monoclonal antibodies, hormones, cytokines.
- chemotherapeutic antitumor agent selected from the group including alkylating drugs, antimetabolites, plant alkaloids, antitumor antibiotics, derivatives platinum derivatives, camptothecin derivatives, altretamine, amsacrine, L-asparaginase, dacarbazine, estramustine
- a chemotherapeutic antitumor agent selected from the group consisting of etoposide, taxol and 5-fluorouracil may be the second active substance.
- the present invention relates to a method for treating an oncological disease, which comprises administering to a mammal in need of such treatment the aforementioned chimeric peptide or pharmaceutical composition or drug.
- the cancer is selected from the group consisting of colorectal cancer, kidney cancer, lung cancer, breast cancer, bladder cancer, pancreatic cancer, uterine cancer, prostate cancer, stomach cancer and ovarian cancer.
- chimeric peptide includes a peptide having a specific sequence for binding functional and transport fragments in a chimeric peptide molecule to any sequence of any length, including through additional amino acid residues (from 1 to 50) linking the two above fragments while the amino acid transport sequence, as an option, can be attached to the C-end of the specified functional sequence by groups X, where X is an amino acid sequence containing from 1 to 50 amino acid residues.
- Methods for producing a chimeric peptide include both the solid-phase method, presented in documents RU2297241, 11/22/2004 and RU2435783, 09/29/2010, and the genetic engineering method, presented in documents RU2297241, 11/22/2004 and RU2435783, 09/29/2010. A study of the properties of these chimeric peptides is given in document RU2435783.
- SERKRGRQTYTRYQTL ELEKEFHFNRYLTRRR RIEIAHALCLTE- Peptides 1-3 consist of the functional part of pl6IN 4a and the internalizable pAntp sequence and differ in the location of the functional group relative to the ⁇ -, C-ends of the molecule and in the presence of an insert for peptide 3 (obtained by genetic engineering method).
- Peptides pl6_pAntp (1-2) differ in the location of the functional group pl6INK4a: peptide 1 - pl6INK4a is located at the C-terminus of the molecule, peptide 2 - pl6INK4a is located at the applimonymill ⁇ Canal-terminus, and the peptides were obtained by solid-phase synthesis.
- the functional group pi 6INK4a is located at the emmeinclin ⁇ réelle-end, but there is an insert of 44 AKOs.
- the term “functional fragment” represents any polypeptide sequence of any size or any structure or molecule to fulfill the functions claimed herein, including the amino acid sequence of SEQ ID NO: 1 or SEQ ID NO: 2, or SEQ ID NO: 3, or SEQ ID NO: 4 SEQ ID NO: 5 or SEQ ID NO: 6 or SEQ ID NO: 8 or SEQ ID NO: 8 or SEQ ID NO: 9 or SEQ ID NO: 10 or SEQ ID NO: 11 or SEQ ID NO: 12 or SEQ ID NO: 13 or SEQ ID NO: 14 or SEQ ID NO: 15 or SEQ ID NO: 16 or SEQ ID NO: 17 as well as sequences that are 60% or more homologous to them.
- antiproliferative activity includes the ability of cyclin kinase inhibitors or compositions including cyclin kinase inhibitors to exert a cytostatic and cytotoxic effect on malignant and benign tumor cells.
- transport sequence includes any transport sequence. Any transport sequence can be used provided that the claimed functional sequence included in any other polypeptide sequence of any size or any other structure or molecule performs the functions specified in this document.
- Herpes simplex virus VP22 (pAntp) peptide sequences can be used as a transport agent for transferring a cyclin kinase inhibitor into target cells, for example, RQIKIWFQNRRM WKK (SEQ ID NO: 6).
- Tat is a transactivating protein in the AIDS virus.
- a pharmaceutically acceptable carrier may include binders, wetting agents, disintegrants, excipients, solubilizers, dispersing agents, stabilizers, suspending agents, coloring agents and flavoring agents.
- a pharmaceutically acceptable carrier may include buffering agents, preservatives, analgesics, solubilizers, isotonic agents and stabilizers.
- a pharmaceutically acceptable carrier may include bases, excipients, lubricants and preservatives.
- the pharmaceutical compositions of the present invention can be obtained in the form of various dosage forms using the above pharmaceutically acceptable carriers. So, for example, for oral administration, the pharmaceutical composition can be obtained in the form of tablets, troches, capsules, elixirs, suspensions, syrups or cachets. For drugs, administered by injection, the pharmaceutical composition can be obtained in the form of a single dosage form, such as a bottle containing drugs for repeated administration, or an ampoule for the introduction of a single dose.
- the pharmaceutical composition may be prepared in the form of solutions, suspensions, tablets, capsules and sustained release preparations.
- examples of carriers, excipients and diluents suitable for the manufacture of pharmaceutical preparations are lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, gum arabic, alginate, gelatin, calcium phosphate, calcium silicate, cellulose , methyl cellulose, microcrystalline cellulose, polyvinylpyrrolidone, water, methyl hydroxybenzoate, propyl hydroxybenzoate, talc, magnesium stearate and mineral oils.
- pharmaceutical preparations may include fillers, anticoagulants, lubricants, moisturizers, perfumes, emulsifiers and antiseptics.
- the dose of a drug of the present invention used as a carrier can be determined depending on several factors, including, the type of disease being treated, route of administration, age, gender and weight of the patient, severity of the disease of the patient, and type of drug used as an active ingredient.
- alkylating agents includes: 1. Alkyl sulfonates (busulfan, threosulfan).
- Chlorethylamines (bendamustine, chlorambucil, cyclophosphamide, ifosfamide, melphalan, trophosphamide).
- antimetabolites includes:
- Purine antagonists cladribine, fludarabine, 6-mercaptopurine, pentostatin,
- plant alkaloids includes:
- Podophyllotoxins etoposide, teniposide
- Taxanes (docetaxel, paclitaxel).
- Vinca-alkaloids (vincristine, vinblastine, vindesine, vinorelbine).
- antibiotics includes:
- Anthracyclines (daunorubicin, doxorubicin, epirubicin, idarubicin, mitoxantrone). 2. Other antitumor antibiotics (bleomycin, dactinomycin, mitomycin, plicamycin).
- platinum derivatives includes: carboplatin, cisplatin, oxaliplatin.
- camptothecin derivatives includes: irinotecan, topotecan.
- the term “monoclonal antibodies” includes: edercolomab, rituximab, trastuzumab.
- hormones includes:
- Antiestrogens tamoxifen, toremifene, droloxifene.
- Aromatase inhibitors (formestane, anastrozole, exemestane).
- Progestins (medroxyprogesterone acetate, megestrol acetate).
- LH-RH agonists buserelin, goserelin, leuprolein acetate, triptorelin).
- Estrogens (phosphestrol, polyestradiol).
- cytokines includes:
- Growth factors (filgrastim, lenograstim, molgramostim, erythropoietin, thrombopoietin).
- Interferons ( ⁇ -interferons, ⁇ -interferons, ⁇ -interferons).
- Interleukins (interleukin-2, interleukin-3, interleukin-P).
- cancer includes both malignant and benign tumors.
- Figure 1 Changes in the level of apoptosis (annexin-positive particles) of blood mononuclear cells when peptides D37K, F26K-1 and W26K-1 are introduced into the cell medium at various concentrations, average values.
- the incubation time is 24 hours.
- Figure 2 The change in the number of “live” / intact cells upon incubation of the cells of the mononuclear fraction of the blood of healthy donors with the studied peptide sequences D37K, F26K-1 and W26K-1 in different concentrations.
- the incubation time is 24 hours.
- FIG. 3 Change in the level of apoptosis in the culture of HCT-116 cells during incubation with the studied peptide sequences.
- the incubation time is 24 hours.
- FIG. 4 Change in the level of apoptosis in MCF-7 cell culture during incubation with the studied peptide sequences.
- the incubation time is 24 hours.
- FIG. 5 Change in the number of dead cells, including propidium iodide, culture HCT-116, incubation with the studied peptide sequences for 24 hours. Peptide concentrations 5 ⁇ m, 1 ⁇ m, 20 ⁇ m, 40 ⁇ m
- FIG. 6 Change in the number of dead cells, including propidium iodide, MCF-7 culture, incubation with the studied peptide sequences for 24 hours.
- Peptide concentrations are 5 ⁇ m, YumkM, 20 ⁇ m, 40 ⁇ m.
- FIG. 9 Changes in the number of cells in S and G2 / M phases during 24-hour incubation of actively proliferating cells of the MCF-7 and HCT-1 16 lines with peptide sequences D37K, F26K-1, F26K-2, W26K-1, W26K-2 concentrations of 10 and 40 ⁇ M.
- FIG. 10 Change in cell level in the GO / Gl phase of the cell cycle in the HCT-116 culture upon incubation of a synchronized culture with the studied peptide sequences at concentrations of 40 ⁇ M.
- FIG. 12 Change in cell level in the GO / Gl phase of the cell cycle in A549 culture upon incubation with a synchronized depleted culture medium with the studied peptide sequences at 40 ⁇ M concentrations.
- FIG. 13 The change in the level of cells in the S-phase of the cell cycle in the A549 culture upon incubation with a synchronized depleted culture medium with the studied peptide sequences at concentrations of 40 ⁇ M.
- FIG. 14 Differences in the S-phase level in the A549 cell culture, at incubation times of 0, 4, 6 and 8 hours with the peptide sequences F26K-1, W26K-1 and D37K at concentrations of 40 ⁇ M.
- FIG. 15 The change in the number of cells in the GO / Gl phase of the cell cycle upon incubation of SKOV cells with the studied peptides for 24 hours.
- Fig.16 Changes in the number of cells in the S + G2 / M phases of the cell cycle upon incubation of SKOV cells with the studied peptides for 24 hours.
- FIG. 17 Change in the apoptosis level in SKOV cell culture during incubation with the studied peptides for 24 hours, estimated as a hypodiploid peak in DNA histograms. Peptide concentrations were 5 ⁇ M, 10 ⁇ M, 20 ⁇ M, 30 ⁇ M, 40 ⁇ M. The culture was previously synchronized in the G0 / G1 phase by the depleted culture medium.
- FIG. 18 Changes in the level of Bcl-2 protein in HCT-116 cells during incubation with the sequences D37K, F26K-1, F26K-2, W26K-1 and W26K-2.
- the incubation time is 24 hours.
- peptides D37K and W26K-1 have a minimal effect, reducing the level of Bcl-2-positive cells in culture by 5% when incubated for 24 hours and a concentration of peptides of 40 ⁇ m.
- Peptides W26K-2 and F26K-1 reduced the level of Bc1-2 more than 15%.
- FIG. 19 Change in the level of phosphorylated pRb in the MCF-7 culture during incubation with the studied peptide sequences D37K, F26K-1, F26K-2, W26K-1 and W26K-2.
- the incubation time is 24 hours, the concentration of peptides: A - 10 ⁇ M, B - 40 ⁇ M.
- FIG. 20 Change in the level of "underphosphorylated" pRb in the cell culture of HCT-1 16 during incubation with the studied peptide sequences.
- A concentration of peptides 10 ⁇ M;
- B concentration of peptides — 40 ⁇ M.
- FIG. 21 Change in the level of "underphosphorylated" pRb in SKOV cell culture upon incubation with the studied peptide sequences.
- A peptide concentration of 10 ⁇ M
- B peptide concentration of 40 ⁇ M.
- FIG. 22 Dependence of the number of dead cells of the HCT-1 16 line on the concentration of drugs (Etoposide, Taxol). The cytotoxic effect was recorded using the MTT test. The incubation time was 24 hours, drugs in concentrations of 1, 10 and 30 ⁇ m.
- FIG. 23 Dependence of the number of dead cells of the HCT-116 line on the concentration of internalizable sequences (F26K-1, D37K). The cytotoxic effect was recorded using the MTT test. The incubation time was 24 hours, sequences in concentrations of 1, 10 and 30 ⁇ M. The cytotoxic effect was higher for the F26K-1 peptide; there is a concentration dependence.
- FIG. 24 The combined effect on the NST-116 cells of the D37K and LP sequences (Taxol, Etoposide), concentrations of 1, 10 and 30 ⁇ M, incubation time 24 hours.
- FIG. 25 The combined effect on the culture of HCT-1 16 sequences F26 -1 at concentrations of 1, 10 and 30 ⁇ m and etoposide in the same concentrations. Incubation time 24 hours, analysis - MTT test.
- FIG. 26 The combined effect on the culture of HCT-1 16 sequences F26 -1 at concentrations of 1, 10 and 30 ⁇ m and Taxol in the same concentrations. Incubation time 24 hours, analysis - MTT test.
- FIG. 27 The study of the combined effects of Taxol and sequences D37K (A) and F26K-2 (B) on the culture of MCF-7. Concentrations of drugs 10, 20, 30 ⁇ m, incubation time 24 hours.
- FIG. 28 Investigation of the combined effects of 5-fluorouracil and the D37K (A) and F26K.-2 (B) sequences on the MCF-7 culture. Concentrations of drugs 10, 20, 30 ⁇ m, incubation time 24 hours.
- FIG. 29 Change in apoptosis level in H460 culture during incubation of cells with peptide sequences (A) and the combined effect of etoposide and sequences (B). Incubation time 24 hours, PI staining, fixed samples.
- FIG. 30 Change in the level of apoptosis in the H460 culture during incubation of cells with peptide sequences (A) and the combined effect of etoposide and sequences (B). Incubation time 24 hours, AnnexinV-PI stain.
- FIG. 31 Change in the level of apoptosis in the H460 culture upon incubation of cells with peptide sequences upon preliminary incubation with etoposide at a concentration of 10 ⁇ M. Peptide incubation time 24 hours, AnnexinV-PI stain.
- FIG. 32 Change in the level of apoptosis in the H460 culture upon incubation of cells with peptide sequences upon preliminary incubation with etoposide at a concentration of 10 ⁇ M.
- the incubation time with peptides is 24 hours, PI staining with preliminary fixation of samples.
- FIG. 33 The distribution of pAntp_ l6 protein in A549 cells over time. 1, 15 and 30 minutes after the addition of protein. Laser scanning microscope Leika.
- Fig. 34 Changes in the tumor volume of transplanted cells in athymic mice when the chimeric internalized peptide Antp_pl6 was introduced into the tumor.
- the mice were transplanted with A549 cell culture and the Antp_pl6 peptide was administered at doses of 0.1 and 0.2 mg.
- Fig. 35 Changes in the tumor volume of transplanted cells in athymic mice with the introduction of the chimeric internalized peptide Antp_l6 into the tumor.
- the mice had perivitis of HCT-116 cells, the peptide was administered at a dose of 0.1 mg.
- FIG. 36 Photographs of experimental animals at the time of 7 injection of the studied internalizable peptide P16_Antp.
- a and B are photographs of mice with transplanted A549 cells, A is a mouse from the control group on day 1 of the experiment, the tumor has a size of 6.0x7.0 mm.
- Figures C and D are mice with transplanted HCT-116 cells, C is a mouse from the control group on the 18th day after the inoculation of tumor cells (tumor size 1 1.5 x 13.5 mm).
- Fig. 37 Two-parameter cytogram of breast cells.
- the X axis shows PI staining
- the Y axis shows cytokeratin stain.
- Region - “cytokeratin-positive apoptosis” is indicated by an arrow.
- Example 1 The study of the effect of peptide sequences D37K, F26K-1, W26K-1 on non-fissile peripheral blood mononuclear cells
- the studied peptides were added to the cell suspension at concentrations of 10, 20, 30, 40, 50, and 60 ⁇ M; the peptides were dissolved in PBS. Incubation was 24 hours at 37 ° C and 5% C0 2 in RPMI culture medium (10% PBS).
- Example 2 The study of cytotoxic activity on proliferating cell lines
- cell cultures were plated in 24-well plates in an amount of 1 * 10 4 cells per well, incubated for 48 hours at 37 ° C and 5% C0 2 , DMEM medium (PanEco, Russia) containing glutamine, gentamicin, 10% FBS. After this incubation, cell cultures formed a loose monolayer.
- DMEM medium PanEco, Russia
- the culture medium was replaced by a medium containing the studied peptides in concentrations of 5 ⁇ m, YumkM, 20 ⁇ m, 40 ⁇ m; in control samples, the medium contained 20 ⁇ l DMSO to determine the effect of the solvent (peptides were dissolved in DMSO).
- the incubation time is 24 hours.
- the cells were carefully removed from the substrate using trypsin (the cells in the wells with peptides attached more strongly than the control samples), washed from the medium by centrifugation at 3000 vol. within 7 minutes, the supernatant was removed and annexation V / PI double label stained.
- the analysis was carried out on a flow cytometer, the number of cells including Annexia V — apoptosis, the number of cells including propidium iodide — dead cells, and the number of intact cells — living cells were estimated.
- the number of dead cells also increases when peptides are introduced into the culture medium and has a concentration dependence ( Figures 5, 6).
- the number of living cells has an inverse relationship with the concentration of peptide sequences introduced into the medium (Figs. 7, 8).
- the values at the level of “early” apoptosis were 41.8% for the F26K-1 sequence and 45.2% for the W26K-1 sequence.
- the level of “early” apoptosis was 37.6%.
- the number of particles with fragmented DNA in this culture during incubation for 24 hours with sequences F26K-1 and W26K-1 was 42.6% and 44.1%, respectively.
- the level of fragmented DNA during incubation with the D37K sequence was 31.5%; the level of fragmented DNA in the control samples for both cultures did not exceed 8%.
- the experiments included the synchronization of cells in the G0 / G1 phase of the cell cycle using a depleted culture medium.
- Cells in a 24-well plate were kept for 48 hours in a medium containing 0.5% PBS, after which the synchronization block was removed by replacing the medium containing 5% PBS and the studied peptides in various concentrations. They were incubated for 24 hours, and then the cells were removed from the substrate using trypsin, washed in FSB, and fixed in ethanol.
- Figures 15, 16 show the change in the number of cells in the phases G0 / G1 and S + G2 / M, for all the studied peptides, an increase in the number of cells in the GO / Gl phase and a decrease in proliferating cells (S + G2 / M phases) with increasing peptide concentrations.
- a slightly lower antiproliferative effect was observed in this case for the sequence W26K-2.
- the sequences F26K-1, F26K-2, W26K-1 caused a delay in the proliferation of SKOV cell lines without significant differences.
- the level of apoptosis correlates with the concentration of introduced peptide and increases from 17.8% in the control sample to 31.2% when incubated for 24 hours with F26K-1 peptide at a concentration of 40 ⁇ M, and up to 35, 3 % upon incubation with the W26K-2 peptide (40 ⁇ M) (Figure 17).
- Example 5 The study of changes in the amount of phosphorylated pRb during incubation of cell cultures with peptide sequences
- Activation of intrinsic pl6INK4a in the cell leads to inhibition of pRb phosphorylation.
- the accumulation of underphosphorylated pRb leads to inhibition of E2F1 and a decrease in the expression of cyclins A and B, which is one of the key mechanisms in stopping the cell cycle.
- By the amount of phosphorylated pRb one can judge the activity of p16.
- the level of “underphosphorylated” pRb begins to increase and at a certain point (4 or 6 hours of incubation), depending on the cell line, reaches its maximum value and then begins to decrease .
- the level of "underphosphorylated” pRb begins to increase later and reaches its maximum value after 12-18 hours of incubation, and the delay in reaching the maximum level of pRb depends on the concentration of peptide sequences.
- the sequences with F26K-2 and W26K-2 had the greatest delay in the formation of “underphosphorylated” pRb.
- the F26K-1 and F26K-2 sequences had the greatest delay in the formation of “underphosphorylated” pRb; for these sequences, the maximum level of “underphosphorylated” pRb, at a peptide concentration of 10 ⁇ M, was observed after 16 hours of incubation, and at a concentration of 40 ⁇ m after 20 hours.
- the delay effect was observed to be the same in time, but the level of “underphosphorylated” pRb was lower.
- FIG. 21 shows the change in the level of “underphosphorylated” pRb in SKOV cell culture when exposed to cells of the D37K, F26K-1, F26K-2, W26K-1, W26K-2 sequences at concentrations of 10 ⁇ M (A) and 40 ⁇ m (B).
- the studied peptide sequences D37K, F26K-1, F26K-2, W26K-1 and W26K-2 are able to induce apoptosis in actively proliferating cells and inhibit proliferation processes.
- the sequences F26K-1 and F26K-2 have the most pronounced cytotoxic and cytostatic effects, upon incubation with which apoptosis has slightly higher values for proliferating cells, proliferation is delayed (an increase in the number of cells in the G0 / G1 phase of the cell cycle) , a decrease in the level of Bc1-2 having a concentration dependence.
- cytotoxic and cytostatic effects are also observed, but less pronounced.
- This method is based on the ability of mitochondrial and cytoplasmic dehydrogenases of living metabolically active cells to restore unpainted forms of 3-4,5-dimethylthiazol-2-yl-2,5-diphenyl terrazole (MTT reagent) to a blue crystalline pharmacazane soluble in dimethyl sulfoxide (DMSO).
- MTT reagent 3-4,5-dimethylthiazol-2-yl-2,5-diphenyl terrazole
- Figure 22 shows the change in the number of dead cells under the influence of drugs on cell culture.
- the cytotoxic effect of etoposide in this concentration range and for this cell line was minimal. Taxol exerted a pronounced cytotoxic effect at a concentration of 30 ⁇ M.
- the F26K-1 sequence induces cell death, and the dependence of the number of dead cells on the concentration of the sequence in the culture medium is observed (Figure 23).
- MCF-7 breast cancer
- LP 5-fluorouracil and Taxol were investigated (in cytotoxicity studies, this sequence had the most pronounced effect on the MCF-7 culture).
- Cells were grown on 24-well plates up to 70% of the monolayer, then the medium was replaced with a medium containing the studied sequences and drugs at concentrations of 10, 20, and 30 ⁇ M. The incubation time was 24 hours.
- the cells that entered into apoptosis were analyzed by staining with annexin-propidium iodide, by flow cytometry.
- Figure 29A shows the change in apoptosis level in the H460 culture during incubation of cells with peptide sequences without etoposide, incubation time 24 hours, apoptosis was analyzed as a subdiploid peak.
- Figure 29B an increase in apoptosis during cell incubation with both sequences and etoposide.
- Figure 30 presents the same samples, but stained with the double AnnexinV-PI label, an increase in early apoptosis, annexin positive cells when exposed to peptide sequences (A) on the culture, and a summation of the effects of the peptide sequences and Etoposide (B).
- Example 7 The study of the penetration of internalizable peptides.
- FITC fluorescent label fluorescein-isothiocyanate
- the most objective data on the accumulation of the peptide inside the cell were obtained using the method of scanning laser microscopy. Protein labeled with fluorescein isothiocyanate was dissolved in 0.9% NaCl. A549, 293 cell lines were grown on sterile glass slides and placed in a special chamber directly under the microscope eyepieces. The medium was replaced with the medium with the studied protein. Protein saturation was observed over time. In addition, a layer-by-layer cell scan was performed to determine the localization of the peptide.
- Lymphocyte fluorescence was measured under the action of the pl6-pAntp-i> HTLJ protein at pH 7.5 and pH b.O.
- the principle of the method is based on a lower quantum yield of FITC fluorescence in solutions with a more acidic pH. Since the measurement speed is fast enough, the pH inside the cell cannot change.
- Lymphocytes were incubated with the peptide for 1-15 minutes, after which a 20-fold volume of phosphate buffer with pH 6.0 and pH 7.5 was immediately added to them. In this case, the difference in fluorescence intensity was estimated. In most measurements, the fluorescence intensities did not significantly differ after 15 minutes of incubation. Thus, it can be assumed that after 15 minutes of incubation, the peptide completely penetrates into the cell. To study the rate of accumulation of the peptide inside the cell, flow cytometry was used. For this, the FITC-labeled peptide was introduced directly into the measuring tube of a flow cytometer, which made it possible to record the dynamics of changes in cell fluorescence.
- the peptide penetrates into tumor cells at a high speed. The time to reach maximum concentration is less than 1 min.
- Example 8 The study of the antitumor activity of the peptide D37K in vivo (local administration)
- nude mice In nude mice (Nude), the antitumor activity of the chimeric internalized peptide D37K was studied.
- mice were inoculated with tumor cultures of human cells of lines A549 and HCT-1 16 in an amount of about 1 million cells per mouse.
- A549 cells were inoculated into 39 mice, of which 20 mice made up the control group, they were subsequently given a placebo. 10 mice made up 1 experimental group. After the formation of a palpable tumor (4 days after transplantation of cells), they began to inject the studied peptide at a dose of 0.1 mg directly into the tumor.
- mice constituted the 2nd experimental group; after the formation of the tumor node, on the 4th day of inoculation, 0.2 mg of the peptide was also introduced into the tumor bed.
- the peptide in the experimental groups was administered once every two days. The experiment lasted 24 days.
- mice When the mice were injected with transplantable human culture NST-116, the animals were divided into two groups: control - 10 mice, which were subsequently not administered the studied peptide and the experimental group (10 mice), which were administered the studied chimeric peptide P16_Antp at a dose of 0.1 mg in the region tumor node.
- the experiment lasted 28 days, 11 injections of the peptide were made in the experimental group, the first injection was made on day 6 after the transplantation of tumor cells. The tumor node from HCT-116 cells was large and ulcerated.
- the control group on the 28th day of the experiment, the average tumor volume was 679 mm 3 ; 3 mice died during the experiment.
- a lower tumor growth rate was observed (Fig. 35), on the 28th day of the experiment, the average tumor volume was 225.4 mm 3 , there were 2 dead animals in the experimental group.
- Example 9 The study of the cytotoxic properties of D37K in short-term cultures of human tumors The antitumor activity of D37K was investigated. 150 mg of D37K peptide were synthesized by solid-phase synthesis. To study the effects on human tumors, the short-term culture method was used.
- Short-term cultures were obtained from operational material. The site for the preparation of culture was taken, if possible, as soon as possible after the operation and with the participation of the pathologist. A section of tissue was cut out, an average of 1.5 cm 3 . The tissue was mechanically crushed, the cell suspension was placed in RPMI medium containing 5% PBS. After 24 hours of incubation at 37 ° C and 5% C g, the medium was replaced with a medium containing a chimeric peptide (pl 6_Antp at a concentration of 40 ⁇ mol), or for a number of experiments on Taxol at a concentration of 100 nMol or 500 nMol containing both the peptide and Taxol . In control samples, the medium was replaced with fresh. The first point was shot - 0 hours.
- Apoptosis levels were analyzed 24 and 48 hours after the addition of peptides at a concentration of 40 ⁇ M. Part of the experiments was carried out to study the combined cytotoxic effect of traditional chemotherapeutic drugs and D37K peptide on tumor cells.
- Example 10 The study of the antitumor activity of the peptide D37K The total results on the cytotoxic activity of the peptide D37K are shown in Table 3.
- Table 3 The average level of induced apoptosis in short-term tumor cultures when exposed to peptide D37K. (24 hours, 40 kM).
- Example 11 A study of the cytotoxic effect on breast fibroadenoma cells.
- the results obtained revealed a spectrum of human tumors sensitive to the D37K peptide. It was found that such localizations as breast cancer, colorectal cancer, stomach cancer, bladder cancer, and kidney cancer are promising objects for further study of the cytotoxic (antitumor) effect of the studied peptide. The results are new, because in the available literature there is no data on the study of the effect of the analyzed peptide on human tumors.
Abstract
Description
Claims
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP14778337.7A EP2982682A1 (en) | 2013-04-03 | 2014-03-27 | Chimeric peptide and pharmaceutical composition for treating oncological diseases |
JP2016506285A JP2016520547A (ja) | 2013-04-03 | 2014-03-27 | 腫瘍性疾患を治療するためのキメラペプチド及び医薬組成物 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EA201300313 | 2013-04-03 | ||
EA201300313A EA028151B1 (ru) | 2013-04-03 | 2013-04-03 | Химерный пептид и фармацевтическая композиция для лечения онкологических заболеваний |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2014163535A1 true WO2014163535A1 (ru) | 2014-10-09 |
Family
ID=51658707
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/RU2014/000199 WO2014163535A1 (ru) | 2013-04-03 | 2014-03-27 | Химерный пептид и фармацевтическая композиция для лечения онкологических заболеваний |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP2982682A1 (ru) |
JP (1) | JP2016520547A (ru) |
EA (1) | EA028151B1 (ru) |
WO (1) | WO2014163535A1 (ru) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6569833B1 (en) | 1995-09-21 | 2003-05-27 | Cyclacel Limited | Cyclin dependent kinase binding peptides |
RU2297241C2 (ru) | 2004-11-22 | 2007-04-20 | Государственное учреждение Российский научный центр рентгенорадиологии Министерства здравоохранения и социального развития | Химерный белок для лечения злокачественных лимфом |
RU2435783C1 (ru) | 2010-09-29 | 2011-12-10 | Общество С Ограниченной Ответственностью "Метамакс" | Химерный пептид и фармацевтическая композиция для лечения онкологических заболеваний |
EA017179B1 (ru) * | 2011-04-06 | 2012-10-30 | Ооо "Метамакс" | Фармацевтическая композиция для лечения гиперпролиферативных заболеваний и её применение |
-
2013
- 2013-04-03 EA EA201300313A patent/EA028151B1/ru not_active IP Right Cessation
-
2014
- 2014-03-27 EP EP14778337.7A patent/EP2982682A1/en not_active Withdrawn
- 2014-03-27 JP JP2016506285A patent/JP2016520547A/ja not_active Ceased
- 2014-03-27 WO PCT/RU2014/000199 patent/WO2014163535A1/ru active Application Filing
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6569833B1 (en) | 1995-09-21 | 2003-05-27 | Cyclacel Limited | Cyclin dependent kinase binding peptides |
RU2297241C2 (ru) | 2004-11-22 | 2007-04-20 | Государственное учреждение Российский научный центр рентгенорадиологии Министерства здравоохранения и социального развития | Химерный белок для лечения злокачественных лимфом |
RU2435783C1 (ru) | 2010-09-29 | 2011-12-10 | Общество С Ограниченной Ответственностью "Метамакс" | Химерный пептид и фармацевтическая композиция для лечения онкологических заболеваний |
EA017179B1 (ru) * | 2011-04-06 | 2012-10-30 | Ооо "Метамакс" | Фармацевтическая композиция для лечения гиперпролиферативных заболеваний и её применение |
Non-Patent Citations (2)
Title |
---|
DEROSSI D. ET AL.: "The third helix of the Antennapedia homeodamain translocates through membranes", J.BIOL. CHEM., vol. 269, 1994, pages 10444 - 10450 |
MORRIS MC ET AL.: "A peptides carrier for the delivery of biologically active proteins in mammalian cells", NAT. BIOTECHNOLOGY, vol. 19, 2001, pages 1173 - 1176 |
Also Published As
Publication number | Publication date |
---|---|
EA201300313A1 (ru) | 2014-10-30 |
EP2982682A1 (en) | 2016-02-10 |
EA028151B1 (ru) | 2017-10-31 |
JP2016520547A (ja) | 2016-07-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Kumar et al. | Intra-tumoral metabolic zonation and resultant phenotypic diversification are dictated by blood vessel proximity | |
CN107271675B (zh) | 抗人adrb3单克隆抗体及其在疾病诊断和治疗中的应用 | |
Yamamura et al. | IGF-I differentially regulates Bcl-xL and Bax and confers myocardial protection in the rat heart | |
Mello et al. | Adenosine uptake is the major effector of extracellular ATP toxicity in human cervical cancer cells | |
JP6113850B2 (ja) | がん性組織の治療およびがん性腫瘍の再発および転移を予防するための医薬組成物の調製のためのヘモグロビン系酸素運搬体の使用方法 | |
BR112012029975B1 (pt) | peptídeo e composição farmacêutica como medicamento | |
US20220389060A1 (en) | Synthetic peptide sp2 and application thereof | |
Cannavo et al. | Prothymosin alpha protects cardiomyocytes against ischemia-induced apoptosis via preservation of Akt activation | |
Vismara et al. | Platelet-derived extracellular vesicles regulate cell cycle progression and cell migration in breast cancer cells | |
CN108103026A (zh) | 用于肿瘤免疫治疗的γδ-T细胞外泌体及其制备方法 | |
Shi et al. | Kaji-ichigoside F1 and rosamultin protect vascular endothelial cells against hypoxia-induced apoptosis via the PI3K/AKT or ERK1/2 signaling pathway | |
Pia Pescarolo et al. | A retro‐inverso peptide homologous to helix 1 of c‐Myc is a potent and specific inhibitor of proliferation in different cellular systems | |
Gao et al. | Mitochondrion-targeted supramolecular “nano-boat” simultaneously inhibiting dual energy metabolism for tumor selective and synergistic chemo-radiotherapy | |
RU2435783C1 (ru) | Химерный пептид и фармацевтическая композиция для лечения онкологических заболеваний | |
CN107602670A (zh) | 一种可拮抗ewsr1蛋白rna结合活性的多肽eip‑22及其应用 | |
CN114605501B (zh) | 一种可拮抗fus蛋白rna结合活性的多肽fip-21及其应用 | |
WO2014163535A1 (ru) | Химерный пептид и фармацевтическая композиция для лечения онкологических заболеваний | |
US20230372529A1 (en) | Mitochondria comprising anticancer drug and use thereof | |
JP5852731B2 (ja) | 高増殖性疾患治療のための医薬組成物 | |
CN113521080A (zh) | Cx-5461在制备phf6突变的急性髓系白血病的药物中的应用 | |
RU2369402C1 (ru) | Химерный пептид для лечения эпителиальных и мезенхимальных злокачественных новообразований | |
RU2728870C2 (ru) | Полипептиды для лечения онкологических заболеваний | |
Mohr | KCa channels in breast cancer development, progression and response to endocrine and radiation therapy | |
WO2017024372A1 (pt) | Processo para a produção de células tronco embrionárias símile de carrapatos (acari: ixodidae), composição, seus usos e método de diagnóstico | |
Abouleisa et al. | Transient Cell Cycle Induction in Cardiomyocytes to Treat Ischemic Heart Failure |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 14778337 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2016506285 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
REEP | Request for entry into the european phase |
Ref document number: 2014778337 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2014778337 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: JP |